Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin to prevent cholangitis after metallic stent placement for distal malignant biliary obstruction
jRCTs051210173Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rifaximin in cancer, malignant biliary obstruction (MBO) and cholangiolitis, sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Incidence of cholangitis. Started Apr 2022; status: active, not recruiting.
02
Drugs
rifaximin
03
Conditions
cancermalignant biliary obstruction (MBO)cholangiolitis
Beyond the preview
Go deeper on jRCTs051210173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210173.